▁admin ister ed ▁or ally ▁and ▁developed ▁by ▁P TC ▁Th era pe ut ics ▁in ▁collaboration ▁with ▁Hoff mann - La ▁Ro che ▁and ▁S MA ▁Foundation . ▁, ▁ris di pl am ▁has ▁advanced ▁to ▁phase ▁II / III ▁clin ical ▁tri als ▁across ▁a ▁wide ▁spectrum ▁of ▁sp inal ▁mus cular ▁at ro phy ▁where ▁it ▁has ▁shown ▁encourag ing ▁early ▁results . ▁ ▁Of ▁dis cont in ued ▁clin ical - stage ▁mole cules , ▁R G 3 0 3 9 , ▁also ▁known ▁as ▁Qu in az oline 4 9 5 , ▁was ▁a ▁propriet ary ▁qu in az oline ▁derivative ▁developed ▁by ▁Re pl igen ▁and ▁lic ensed ▁to ▁Pf izer ▁in ▁March ▁ 2 0 1 4 ▁which ▁was ▁dis cont in ued ▁shortly ▁after , ▁having ▁only ▁completed ▁phase ▁I ▁tri als . ▁P T K - S MA 1 ▁was ▁a ▁propriet ary ▁small - m ole c ule ▁sp lic ing ▁mod ulator ▁of ▁the ▁t et racy cl ines ▁group ▁developed ▁by ▁Par ate k ▁Ph arma ce ut ical s ▁and ▁about ▁to ▁enter ▁clin ical ▁development ▁in ▁ 2 0 1 0 ▁which ▁however ▁never ▁happened . ▁R G 7 8 0 0 ▁was ▁a ▁mole c ule ▁a kin ▁to ▁R G 7 9 1 6 , ▁developed ▁by ▁Hoff mann - La ▁Ro che ▁and ▁tri alled ▁on ▁S MA ▁patients ▁in ▁ 2 0 1 5 , ▁whose ▁development ▁was ▁dis con ton ued ▁in ▁ 2